Zeo ScientifiX CEO gets dual 625K option grants

Zeo ScientifiX, Inc. reported that CEO, CFO and 10% owner Ian T. Bothwell received two grants of stock options on June 10, 2026.

Rhea-AI Filing Summary

Zeo ScientifiX, Inc. reported that CEO, CFO and 10% owner Ian T. Bothwell received two grants of stock options on June 10, 2026. Each grant covers 625,000 options to buy common stock at an exercise price of $1.67 per share.

The first grant vested in full on the grant date and is exercisable on a cashless basis for ten years under the company’s 2021 Equity Incentive Plan. The second grant also covers 625,000 options, vests upon achievement of specified performance milestones, is exercisable cashless for up to ten years, and is described as antidilutive for future transactions issuing 10% or more of fully diluted common shares. These are compensation-related awards, not open‑market share purchases.

Insider Trade Summary

Grant/Award: 1,250,000 shares

Grant/Award 2 txns

Insider BOTHWELL IAN T

Role CEO & CFO

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	625,000	$0.00	$0.00
Grant/Award	Stock Options	625,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 1,250,000 contracts (Direct)

Footnotes (2)

1. F1. Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Equity Incentive Plan (the "2021 Plan"). The options vested in full as of the grant date, are exercisable on a "cashless basis" for a period of ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan.
2. F2. Represents the grant of stock options to purchase shares of the Issuer's common stock under the 2021 Plan. The options vest upon the achievement of certain performance milestones, are exercisable on a "cashless basis" during the period commencing on the date they vest and ending ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan. The options are antidilutive for any future transaction that provides for the issuance of 10% or more of the Company's common stock outstanding on a fully diluted basis.

Key Figures

Option grant size (time-vested): 625,000 options Option grant size (performance-based): 625,000 options Exercise price: $1.67 per share +3 more

6 metrics

Option grant size (time-vested) 625,000 options Fully vested grant on June 10, 2026

Option grant size (performance-based) 625,000 options Performance-milestone grant on June 10, 2026

Exercise price $1.67 per share Conversion/exercise price for both option grants

Expiration date June 10, 2036 Ten-year term from award date for each grant

Transaction code A (grant/award acquisition) Compensation-related acquisitions, not open-market buys

Underlying common stock 625,000 shares per grant Each option grant relates to common stock under 2021 Plan

Key Terms

2021 Equity Incentive Plan, cashless basis, performance milestones, antidilutive

4 terms

2021 Equity Incentive Plan financial

"Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Equity Incentive Plan"

cashless basis financial

"The options vested in full as of the grant date, are exercisable on a "cashless basis" for a period of ten (10) years"

An agreement executed on a cashless basis lets a holder convert or exercise a security (like options, warrants, or conversion rights) without paying money upfront; instead the holder receives a smaller number of shares equal in value to what the cash would have purchased. Think of trading a coupon for fewer slices of a cake rather than handing over cash for the full slice. For investors, it affects how much ownership and dilution occur and avoids immediate cash outlays.

performance milestones financial

"The options vest upon the achievement of certain performance milestones, are exercisable on a "cashless basis""

antidilutive financial

"The options are antidilutive for any future transaction that provides for the issuance of 10% or more of the Company's common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Zeo ScientifiX (ZEOX) disclose in this Form 4 filing?

Zeo ScientifiX disclosed that CEO, CFO and 10% owner Ian T. Bothwell received two stock option grants. Each grant covers 625,000 options to buy common shares at an exercise price of $1.67 under the 2021 Equity Incentive Plan.

How many stock options did ZEOX CEO Ian Bothwell receive?

Ian Bothwell received two separate stock option grants of 625,000 options each. Both grants relate to Zeo ScientifiX common stock and were awarded on June 10, 2026 under the company’s 2021 Equity Incentive Plan as compensation.

What are the terms of Ian Bothwell’s fully vested ZEOX option grant?

One grant of 625,000 options vested in full on the grant date. These options are exercisable on a cashless basis for ten years from June 10, 2026 and are subject to all other terms of Zeo ScientifiX’s 2021 Equity Incentive Plan.

How do the performance-based ZEOX stock options for Ian Bothwell work?

The second 625,000-option grant vests only when specified performance milestones are achieved. Once vested, the options are exercisable on a cashless basis for ten years and are characterized as antidilutive if future deals issue 10% or more of fully diluted common shares.

Are Ian Bothwell’s ZEOX option grants open-market stock purchases?

No, these are compensation-related option awards, not open-market purchases of common stock. The Form 4 describes them as grants under the 2021 Equity Incentive Plan, with no cash paid per option on the grant date.

What does cashless exercise mean for the ZEOX stock options granted?

Cashless exercise allows Ian Bothwell to receive net shares without paying the exercise price in cash. Instead, a portion of the underlying shares is typically withheld to cover the exercise cost and related obligations under the plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOTHWELL IAN T

(Last) (First) (Middle)

3321 COLLEGE AVENUE

SUITE 246

(Street)

DAVIE FLORIDA 33314

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zeo ScientifiX, Inc. [ ZEOX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.67	06/10/2026		A(1)		625,000		06/10/2026(1)	06/10/2036	Common Stock	625,000	$0	625,000	D
Stock Options	$1.67	06/10/2026		A(2)		625,000		06/10/2026(2)	06/10/2036	Common Stock	625,000	$0	625,000	D

Explanation of Responses:

1. Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Equity Incentive Plan (the "2021 Plan"). The options vested in full as of the grant date, are exercisable on a "cashless basis" for a period of ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan.

2. Represents the grant of stock options to purchase shares of the Issuer's common stock under the 2021 Plan. The options vest upon the achievement of certain performance milestones, are exercisable on a "cashless basis" during the period commencing on the date they vest and ending ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan. The options are antidilutive for any future transaction that provides for the issuance of 10% or more of the Company's common stock outstanding on a fully diluted basis.

	/s/ Ian T. Bothwell	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)